|1.||Salgado, Helio C: 6 articles (10/2015 - 01/2013)|
|2.||Fazan, Rubens: 6 articles (01/2015 - 01/2013)|
|3.||Prado, Cibele M: 4 articles (10/2015 - 10/2013)|
|4.||Low, Phillip A: 4 articles (08/2008 - 02/2005)|
|5.||da Silva, Carlos Alberto Aguiar: 3 articles (01/2015 - 01/2013)|
|6.||Pohanka, Miroslav: 3 articles (08/2012 - 03/2010)|
|7.||Doctor, Bhupendra P: 3 articles (09/2008 - 12/2005)|
|8.||Singer, Wolfgang: 3 articles (05/2008 - 02/2005)|
|9.||Bajgar, Jirí: 3 articles (01/2008 - 01/2004)|
|10.||Serra, S M: 3 articles (10/2004 - 09/2000)|
12/01/2006 - "Current protection against nerve agent poisoning is pyridostigmine, but its prophylactic efficacy is rather limited. "
04/01/2011 - "pyridostigmine bromide) are used as a pre-treatment for the prevention of organophosphorus poisoning. "
03/01/2005 - "Pyridostigmine is the current pretreatment for nerve agent poisoning and is in use by most of the armed forces in Western countries. "
12/01/1996 - "Pyridostigmine is also recommended by most Western armies for use as pretreatment under threat of chemical warfare, because of its protective effect against organophosphate poisoning. "
06/01/1994 - "As a prophylactic treatment for OP agent poisoning, pyridostigmine has a substantial safety factor, since behavioral toxicity becomes significant only at approximately four times the proposed therapeutic dose."
08/15/1955 - "[Mestinon, a new remedy for myasthenia gravis]."
01/01/1977 - "The urinary clearance of pyridostigmine was studied in six patients with myasthenia gravis. "
01/01/1977 - "Renal clearance of pyridostigmine in patients with myasthenia gravis."
11/01/2010 - "Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial."
01/01/2008 - "Although the dose of pyridostigmine was not optimized before the study, the majority of responders achieved better Quantitative Myasthenia Gravis scores than on pyridostigmine. "
08/01/1995 - "Pyridostigmine may be useful in the management of fatigue in selected patients with PPS. "
12/01/2003 - "67 subjects with increased fatigue and new weakness in one quadriceps muscle showing neuromuscular transmission defects, were included in a randomised, double blind, placebo controlled trial of 60 mg pyridostigmine four times a day for 14 weeks. "
08/01/1995 - "We initiated an open trial of the oral anticholinesterase pyridostigmine, up to 180 mg per day, in 27 PPS patients with generalized fatigue and muscle fatiguability. "
12/01/2015 - "By the age of 34, the patient experienced gradual worsening of fatigue with dyspnoea and pronounced limb weakness, requiring significant increase of pyridostigmine. "
04/01/2006 - "The dose of pyridostigmine remained stable throughout the pregnancy (60 mg every 8 h), and the 3,4-DAP dose was adjusted according to the patient's level of fatigue (20 mg/day, with occasional additional doses of 5 mg). "
04/01/1993 - "The remaining muscle weakness responded well to treatment with pyridostigmine bromide started after the end of the antibiotic therapy. "
03/01/2010 - "Continuous pyridostigmine infusion improves muscle weakness after 7 days and 14 days of immobilization. "
03/01/2010 - "To investigate the effects of continuous pyridostigmine infusion on immobilization-induced muscle weakness. "
10/01/2002 - "Pyridostigmine treatment improved the proximal muscle weakness whereas the ophthalmoparesis remained unchanged in all patients. "
01/01/2006 - "In spite of treatment with pyridostigmine and prednisolone, the symptoms in patient 1 generalized within 4 weeks causing dysphagia, limb muscle weakness and respiratory crisis. "
|5.||Diplopia (Double Vision)
06/01/2012 - "She recently developed unilateral ptosis and diplopia which dramatically improved with pyridostigmine suggesting concomitant MG."
01/01/2000 - "Diplopia and ptosis improved with oral pyridostigmine. "
03/01/2007 - "However, an initial presentation of concurrent ptosis and diplopia and the presence of systemic involvement after follow up were significant factors associated with an insensitivity to pyridostigmine in patients with OMG (p = 0.001 and p = 0.01, respectively). "
03/01/2007 - "There were no significant differences in gender, age, the duration of symptoms before treatment, the dosage of pyridostigmine, and the initial presentations of ptosis or diplopia between the two groups. "
10/01/2005 - "The pyridostigmine group showed resolution in primary gaze diplopia, downgaze diplopia, unilateral ptosis, and bilateral ptosis in 6.9%, 17.2%, 50%, and 76.7% of patients after 1 month of treatment. "
|9.||Insulin-Like Growth Factor I (IGF-1)
|10.||pralidoxime (Protopam Chloride)